Sign inJoin waitlistJoin the waitlist

Samer Srour

Associate Professor of Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2015–2016
Hematology and Medical Oncology
University of Oklahoma Health Sciences Center
2009–2012
Internal Medicine
Staten Island University Hospital
2006–2009
Doctor of Medicine
1999–2003

Research

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Cancer Discovery · 2024 · Last of 25 authors · 144 citations
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
British Journal of Haematology · 2016 · First of 7 authors · Corresponding · 135 citations
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity
Blood Advances · 2021 · 134 citations

Richard Champlin
102 papers
Elizabeth Shpall
94 papers
Partow Kebriaei
84 papers
Muzaffar Qazilbash
82 papers
Qaiser Bashir
78 papers
Yago Nieto
75 papers
Jeremy Ramdial
63 papers · 8 as a fellow
Uday Popat
59 papers
Neeraj Saini
56 papers · 5 as a fellow
Chitra Hosing
54 papers
Krina Patel
45 papers
Robert Orlowski
45 papers

Clinical trials

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2033
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2017–2023
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2014–2021
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2014–2022